



Supporting Table 1. Anaphylactic symptom scoring for mice model.

Scores	Anaphylactic symptoms
0	No symptoms.
1	Scratching and rubbing around the nose and mouth.
2	Swelling around the eyes and mouth; high breathing rate.
3	Wheezing; labored respiration; cyanosis around the mouth and tail.
4	No activity; shivering; muscle contraction.
5	Death.

Supporting Figure 1. Changes of β -hexosaminidase release rate from sensitized RBL-2H3 cell line stimulated by different concentrations of TM.



Supporting Figure 2. Experimental timeline followed in the *in vivo* studies. Groups of female BALB/c mice ($n=6$) were immunized with 50 μg of TM adsorbed in 0.5 mg/mL alum by intraperitoneal injection on days 1, 7, 13, 19, 25 and 31. Mice were stimulated with 100 μg of protein on days 34, 37, 40 and 43 and challenged on day 50 with 1 mg of protein per mouse. Mice were divided into five groups ($n=6$), namely, PBS, TM, CLC⁺, CTG⁺ and OVA. The mice of PBS groups were injected with same volume of PBS, following the same protocol as the target allergenic proteins. PBS and OVA groups were used as negative and positive control, respectively.



Supporting Figure 3. Dot blot inhibition assay of IgG- and IgE-binding capacity. The nitrocellulose membrane was spotted with 2 μ g of native TM and the IgG-/IgE-binding capacity were detected using two mice sera (MS1 and MS2) from each group. HRP-labeled goat anti-mice IgG and goat anti-mice IgE were used as secondary antibodies, respectively.

